Its shares have lost 32 per cent year to date.īig Pharma names on the sidelines of the GLP-1 wave, such as Merck and Co. RMD-N makes devices to treat sleep apnea, which is associated with obesity. ZBH-N, which makes components used in knee replacements, is down by 19 per cent on the year. Companies that make insulin pumps and glucose monitors have seen their shares pummelled – on the order of 50 to 65 per cent downside. Several analysts have predicted that Zepbound is fated to become the single best-selling drug in history.Īs the stock market hype machine has revved up on the weight-loss trade, a great number of companies have been relegated to the ranks of the disrupted.Īny entity profiting from obesity, even in the most indirect way, has been a target for rerating. Goldman Sachs recently forecast that the global market for obesity drugs could hit US$100-billion by 2030 – a number that would have seemed outlandish just a year ago. population is classified as obese and you start to get an idea of the vast market potential.
“These drugs fundamentally change how we treat obesity and diabetes, which is an epidemic,” said Eden Rahim, portfolio manager of the Next Edge Biotech and Life Science Opportunities Fund.Ĭonsider that more than 40 per cent of the U.S.
